TRANS GENIC INC has a total of 11 patent applications. Its first patent ever was published in 2004. It filed its patents most often in China, WIPO (World Intellectual Property Organization) and EPO (European Patent Office). Its main competitors in its focus markets biotechnology, measurement and pharmaceuticals are BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD, BEIJING BIOCYTOGEN CO LTD and ORIGEN THERAPEUTICS INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | China | 3 | |
#2 | WIPO (World Intellectual Property Organization) | 3 | |
#3 | EPO (European Patent Office) | 2 | |
#4 | United States | 2 | |
#5 | Hong Kong | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Measurement | |
#3 | Pharmaceuticals | |
#4 | Agriculture |
# | Technology | |
---|---|---|
#1 | Microorganisms | |
#2 | Peptides | |
#3 | Analysing materials | |
#4 | Animal care | |
#5 | Therapeutic chemical compounds |
# | Name | Total Patents |
---|---|---|
#1 | Shinagawa Shingo | 5 |
#2 | Shimono Akihiko | 4 |
#3 | Yamada Tesshi | 4 |
#4 | Ito Kazunari | 4 |
#5 | Tokashiki Yoshimi | 4 |
#6 | Miyamoto Tomoaki | 4 |
#7 | Araki Kimi | 4 |
#8 | Honda Kazufumi | 4 |
#9 | Okada Seiji | 4 |
#10 | Yamamura Kenichi | 4 |
Publication | Filing date | Title |
---|---|---|
WO2013145331A1 | Humanized mouse | |
CN108456249A | The antibody of anomaly α-actinine -4 | |
US2007161059A1 | N1,n12-diacetylspermine as tumor marker |